Camidge DR - Search Results

1

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.

Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Noonan SA, et al. Among authors: camidge dr. J Thorac Oncol. 2018 Jan;13(1):134-138. doi: 10.1016/j.jtho.2017.08.005. Epub 2017 Aug 24. J Thorac Oncol. 2018. PMID: 28843358 Free PMC article.

2

From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.

Weiss GJ, Bunn PA Jr, Camidge DR. Weiss GJ, et al. Among authors: camidge dr. Oncology (Williston Park). 2006 Nov;20(12):1515-24; discussion 1524-5, 1530, 1535. Oncology (Williston Park). 2006. PMID: 17153906 Free article. Review.

3

The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer.

Camidge DR. Camidge DR. Clin Lung Cancer. 2007 Jul;8(7):413-9. doi: 10.3816/CLC.2007.n.024. Clin Lung Cancer. 2007. PMID: 17681093 Review.

4

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.

Einhorn LH, Bonomi P, Bunn PA Jr, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Einhorn LH, et al. Among authors: camidge dr. J Thorac Oncol. 2008 May;3(5):545-55. doi: 10.1097/JTO.0b013e318170627f. J Thorac Oncol. 2008. PMID: 18449013 Free PMC article. No abstract available.

5

Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.

Erickson TM, Koeppe JR, Miller YE, Stuart RW, Camidge DR. Erickson TM, et al. Among authors: camidge dr. J Thorac Oncol. 2008 Nov;3(11):1353-5. doi: 10.1097/JTO.0b013e31818b1ae1. J Thorac Oncol. 2008. PMID: 18978572 Free article.

6

Mitotic inhibitors.

Camidge DR. Camidge DR. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1074-6. doi: 10.1097/01.JTO.0000361756.09789.56. J Thorac Oncol. 2009. PMID: 19861923 Free article. No abstract available.

7

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

Solomon B, Varella-Garcia M, Camidge DR. Solomon B, et al. Among authors: camidge dr. J Thorac Oncol. 2009 Dec;4(12):1450-4. doi: 10.1097/JTO.0b013e3181c4dedb. J Thorac Oncol. 2009. PMID: 20009909 Free article.

8

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr. Doebele RC, et al. Among authors: camidge dr. Lung Cancer. 2010 Jul;69(1):1-12. doi: 10.1016/j.lungcan.2009.12.009. Epub 2010 Jan 25. Lung Cancer. 2010. PMID: 20092908 Review.

9

Biomarkers are here to stay for clinical research and standard care.

Bunn PA Jr, Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, Franklin W. Bunn PA Jr, et al. Among authors: camidge dr. J Thorac Oncol. 2010 Aug;5(8):1113-5. doi: 10.1097/JTO.0b013e3181e7616e. J Thorac Oncol. 2010. PMID: 20661083 Free article. No abstract available.

10

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Camidge DR, et al. Clin Cancer Res. 2010 Nov 15;16(22):5581-90. doi: 10.1158/1078-0432.CCR-10-0851. Epub 2010 Nov 9. Clin Cancer Res. 2010. PMID: 21062932 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters